Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.8490
+0.0792 (10.29%)
Jun 3, 2025, 11:21 AM - Market open
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -95.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Citius Pharmaceuticals stock ranges from a low of $9.00 to a high of $100. The average analyst price target of $54.5 forecasts a 6,319.32% increase in the stock price over the next year.
Price Target: $54.50 (+6,319.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Citius Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 23, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +960.07% | May 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +960.07% | Feb 18, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +960.07% | Jan 7, 2025 |
| D. Boral Capital | D. Boral Capital | Hold → Strong Buy Upgrades $9 | Hold → Strong Buy | Upgrades | $9 | +960.07% | Dec 30, 2024 |
Financial Forecast
Revenue This Year
n/a
from 296.41M
Revenue Next Year
n/a
EPS This Year
-0.68
from -5.97
EPS Next Year
2.09
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.8M | 82.2M | 183.8M | ||
| Avg | 16.0M | 74.5M | 162.6M | ||
| Low | 15.0M | 66.4M | 140.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -94.3% | 414.1% | 146.7% | ||
| Avg | -94.6% | 365.9% | 118.3% | ||
| Low | -94.9% | 315.4% | 89.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.42 | 4.96 | 6.21 | ||
| Avg | -0.68 | 2.09 | 3.72 | ||
| Low | -2.64 | -0.61 | 1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 196.8% | ||
| Avg | - | - | 78.0% | ||
| Low | - | - | -34.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.